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•This ESMO Clinical Practice Guideline provides key recommendations on the 
management of localised colon cancer  
•Authorship includes a multidisciplinary group of experts from different institutions 
and countries in Europe and abroad 
• Diagnostic work-up is reviewed 
• Key treatment recommendations  





Incidence and epidemiology 
Colorectal cancer (CRC) is the third most common tumour in men and the second 
in women, accounting for 10% of all tumour types worldwide. Incidence is 25% 
higher in males and differs greatly between countries. With more than 600,000 
deaths estimated each year, CRC is the 4th most common cancer-related cause 
of death globally [1-2]. The growing incidence in some countries reflects a 
modification in lifestyle and its consequences related with ‘Westernisation’ such 
as obesity, physical inactivity, alcohol consumption, high red meat intake and 
cigarette smoking [3]. Some data suggest a putative role in colon cancer 
carcinogenesis for factors that cause imbalances in gut microbiota [4, 5].  
The mortality rate in the European Union is 15–20 out of 100 000 in males and 
9–14 out of 100 000 in females and has decreased over time, particularly in 
females. In affected European individuals, 5-year survival ranges from 28.5% to 
57% in men and from 30.9% to 60% in women, with a pooled estimation in 23 
countries of 46.8% in men and 48.4% in women [6]. 
The risk of developing colon cancer depends on factors which can be classified 
into lifestyle or behavioural characteristics and genetically-determined factors. 
Screening tests are modulated according to the individual probability of 
developing CRC [7-9]. Age is considered the major unchangeable risk factor for 
sporadic colon cancer: nearly 70% of patients are >65 years of age and this 
disease is rare before the age of 40 years, even though data from Western 
registries show an increased incidence in the 40–44 year-age group [10]. 
Individuals with any of the following are considered at high risk of colon cancer 
and must be actively screened and in case of inherited syndromes, also referred 
for genetic counselling (see ESMO guidelines for hereditary gastrointestinal 
cancer [11]): 
● a medical history of adenoma, colon cancer, inflammatory bowel disease 
(Crohn’s disease and ulcerative colitis); 




● an inherited cancer syndrome (2%–5% of all CRC), such as familial 
adenomatous polyposis coli and its variants (1%), Lynch-associated 
syndromes (hereditary non-polyposis colon cancer) (2%–4%), Turcot, 
Peutz-Jeghers and MUTYH-associated polyposis syndrome. 
 
SCREENING PRINCIPLES  
CRC arises following progression of normal mucosa to an invasive tumour, 
passing through different intermediate stages of premalignant and invasive 
malignant lesions; this stepwise process facilitates cancer prevention and early 
diagnosis when the tumour is still at an early stage and curable, through 
screening programmes. For average-risk populations, European and American 
evidence-based guidelines for quality assurance in CRC screening [12,13] should 




 Colonoscopic techniques, despite being invasive, have the advantage of 
being both diagnostic and therapeutic.  
 A complete colonoscopy is the recommended method for CRC screening 
in average-risk men and women based on higher sensitivity and specificity 
when compared with other tests [14] [II, B]. The optimal age range for 
testing is 50–74 years [V, D] with an optimal repetition interval for a 
negative test of 10 years [III, C]. 
 Flexible sigmoidoscopy (FS) performed every 5–10 years may be an 
alternative for those who refuse colonoscopy [II, B]. The combination of 
this method with a yearly faecal occult blood test (FOBT) (see below) is 
recommended to reduce the risk of a right colon tumour [III, B]. 
 Other invasive tests including capsule colonoscopy are not recommended 







Non-invasive tests:  
 Non-colonoscopic tests are recommended in average-risk men and 
women from the age of 50 not already taking part in colonoscopic 
screening programs. The optimal frequency of testing is every year and 
no later than every three years [I, B]. A colonoscopy must be performed at 
the earliest convenience when the test results are positive [I, A]. 
 
 Among the available tests, faecal immunochemical testing (FIT) appears 
to be superior to high-resolution guaiac FOBT with respect to the detection 
rate and positive predictive value for adenomas and cancer [III]. Other 
novel methods including DNA-based or tests using other markers (e.g. 
M2-PK) lack formal comparisons of their performance, and integration with 
other assays needs to be monitored. 
 
Screening for high-risk populations is covered in the ESMO guidelines for 
hereditary gastrointestinal cancer [11]. 
 
DIAGNOSIS 
Symptoms and signs 
Colon cancer arises from the mucosa of the bowel, growing both into the lumen 
and the bowel wall, and/or spreading to adjacent organs. Symptoms are 
associated with relatively large tumours and/or advanced disease stages and 
may not be specific for colon cancer. Alterations in bowel habit, general or 
localised abdominal pain, weight loss without other specific causes, weakness, 
iron deficiency and anaemia are the most common symptoms and depend on the 
location and stage of the primary tumour [15, 16]. Colon cancer can occur with 
multiple or synchronous lesions (3.6%) [17] with identical or different histological 
patterns and stages of development. Metachronous primary tumours arise in up 
to 3% of cases during the 5 years after surgery, and the incidence increases up 
to 9% after several decades in long-term survivors, justifying long-term 







A complete work-up should be carried out to achieve an accurate histological 
diagnosis of the primary tumour, assess the baseline characteristics of the patient 
and determine the extent of the disease (see Table 1). 
 
Diagnosis of the primary tumour  
In the absence of a bowel obstruction or massive haemorrhage, which may 
constitute indications of an urgent tumour resection, a total colonoscopy is 
recommended for diagnostic confirmation of colon cancer [I, A]. There are many 
advantages of endoscopy including determination and marking of the exact 
tumour location and biopsy of the lesion, detection and removal of (further) 
synchronous precancerous or cancerous lesions. Combining the limited left-sided 
colonoscopy with computed tomography (CT) colonoscopy is an alternative if full 
colonoscopy is not feasible [I, A] [19]. In cases where complete colonic 
exploration cannot be carried out before surgery, a complete colonoscopy should 
be carried out within 3–6 months [IV, B]. 
 
Assessment of patient baseline status and characteristics  
After colonic tumour diagnosis, clinical examination and laboratory tests must be 
carried out to provide a correct assessment of patient status and characteristics 
before deciding the definitive treatment approach [II, A].  
Besides a comprehensive physical examination [20] [IV], blood tests including 
complete blood count, coagulation, liver and kidney functions tests as well as 
albumin can provide relevant clinical information regarding the patient’s baseline 
conditions and the existence of cancer-related complications [II, A].  
In addition, serum levels of carcinoembryonic antigen (CEA), although not 
sufficient for colon cancer diagnosis themselves in the absence of a confirmatory 
tumour biopsy (because of low specificity and sensitivity), should be evaluated 




detection of metastatic disease [III, A] [21-23]. In addition, CEA determination 
after colon cancer diagnosis is of particular importance since baseline levels add 
information in defining prognosis; a preoperative serum CEA level >5 ng/ml (or 
even >2.35) suggests a worse outcome [21]. 
 
Assessment of distant tumour extension 
Preoperative assessment of tumour extension should be done to determine 
whether the patient should be referred for primary tumour resection or, in the 
presence of unresectable distant metastases, systemic therapy. Approximately 
20% of newly diagnosed colon cancers have synchronous metastasis, the most 
frequently involved organ being the liver (17%), followed by peritoneum (5%), 
lung (5%) and lymph nodes (3%) [24].  
CT of the thoracic, abdominal and pelvic cavities with intravenous contrast 
administration is the preferred radiological method for the evaluation of the 
presence of distant metastases of CRC [II, B]. This test allows evaluation of 
locoregional tumour extension and its complications (e.g. obstruction, perforation, 
fistula, abscess) [25]. However, CT scanning may fail to detect peritoneal 
metastases, where sensitivity is relatively poor and depends on implant 
localisation and size [26,27]. 
Contrast-enhanced magnetic resonance imaging (MRI) permits better definition 
of the soft tissues. It constitutes the reference test when it is necessary to 
evaluate the relationship of locally advanced tumours with surrounding structures 
or in defining ambiguous liver lesions previously detected by CT scan [II, A] [28]. 
Likewise, MRI can substitute for CT scanning in patients with iodine contrast 
allergies or chronic renal insufficiency where glomerular filtration rate is <30 
ml/min [II, A] [29-31].  
Positron emission tomography (PET) with the glucose analogue 18-fluoro-2-
deoxy-D-glucose (FDG-PET), with or without integrated CT (PET/CT), does not 
add significant information to the CT scans on preoperative staging of CRC and 
is not recommended for routine use in staging of localised CRC beyond assisting 






 In the absence of indications for urgent tumour resection, a total 
colonoscopy is recommended for diagnostic confirmation of colon cancer 
and to rule out synchronous tumours. Combining the limited left-sided 
colonoscopy with CT colonoscopy is an alternative if full colonoscopy is 
not possible [I, A]. 
 When not carried out before or during the surgical procedure, a complete 
colonoscopy should be carried out within 3–6 months following tumour 
resection [IV, B]. 
 Comprehensive physical examination and laboratory tests including full 
blood counts, biochemistry, serum CEA must be carried out prior to 
decisions on the definitive treatment approach [III, A]. 
 CT of the thoracic, abdominal and pelvic cavities with intravenous contrast 
administration is the preferred radiological method for the evaluation of 
the extent of CRC [II, B]. 
 Contrast-enhanced MRI constitutes the reference test for evaluation of 
the relationship of locally advanced tumours with surrounding structures 
or in defining ambiguous liver lesions [II, A]. 
 
MANAGEMENT OF LOCALISED COLONIC TUMOURS  
Treatment of adenocarcinomas presenting in adenomas 
Complete en bloc endoscopic resection should be carried out whenever the 
morphological structure of the polyp permits [34]. Endoscopic resection is 
sufficient for hyperplastic or adenomatous polyps, and non-invasive (pTis, i.e. 
intraepithelial or intramucosal) adenocarcinomas [35] (see Figure 1). For (pT1) 
invasive carcinomas, the management is determined by the polyp morphology 
and the presence of histological features associated with adverse outcome [36]:  
 lymphatic or venous invasion;  
 grade 3 differentiation; 




For a pedunculated polyp with a pT1 carcinoma confined to the head, neck and 
stalk (Haggitt 1–3) endoscopic resection with proper follow-up is enough even 
with the presence of submucosal invasion provided that no other unfavourable 
factors are present [IV, B] [38]. However, the presence of any unfavourable factor 
in a sessile or flat polyp (Paris classification) with a pT1 carcinoma, mandates 
surgical resection in patients with average operative risk [IV, B] [39]. The role of 
the surgical resection will be to complete lesion resection and to include lymph 
node removal for optimal risk assessment [IV, B]. In contrast finding positive 
resection margins (<1 mm) constitutes only a risk for local recurrence and can be 
managed by excision repetition or local surveillance [39].  
When surgery is not possible due to significant comorbidities, surveillance 
colonoscopy within 6 months after polyp removal is recommended, as well as 
close oncological follow-up including CT scan to detect lymph node recurrences 
[IV, B] [38, 39].  
 
Management of locally infiltrative colon cancers 
Infiltrative colon cancers cannot be resected by colonoscopy and necessitate 
surgery, with the goal of wide resection of the involved bowel segment and its 
lymphatic drainage [I, A]. The extent of the colonic resection is determined by the 
blood supply and distribution of regional lymph nodes. The resection should 
include a segment of colon of at least 5 cm on either side of the tumour, but wider 
margins are often included due to the mandatory ligation of the arterial blood 
supply [IV, B]. En bloc colonic and mesentery resection is recommended in order 
to clearly define stage II versus stage III and to identify and eradicate potential 
lymph node metastases, at least 12 lymph nodes should be resected when 
feasible [IV, B] [40]. Likewise, en bloc resection of adjacent organ invaded 
portions must be carried out in case of pT4b [41] [I, B].  
During the procedure a complete assessment of the peritoneal cavity and ovaries 
should be carried out to investigate for possible metastasis [41] [I, C]. (See ESMO 
guidelines for metastatic colorectal cancer for the management patients with 
removed metastasis [42]).  




technical expertise is available in the absence of contraindications in view of 
reduced morbidity, improved tolerance and similar oncological outcomes [I, C] 
[43, 44].  
Obstructive CRCs can be treated in one or two stages. Two-stage procedures 
can include colostomy followed by colonic resection or, in the case of bowel 
perforation, Hartmann’s procedure followed by colostomy closure and 
anastomosis. One-stage procedures are preferred when carried out by 
experienced teams; subtotal colectomy and ileorectal anastomosis or segmental 
resection after intraoperative colonic lavage are alternatives in selected cases 
[III]. Colonic stenting [45, 46] can be used in expert centres as a bridge to elective 
surgery, especially in patients with higher rates of postoperative complication 
after emergency surgery [>70 years old and/or American Society of 
Anesthesiologists (ASA) >II] [II]. 
 
Recommendations: 
 En bloc endoscopic resection of the polyp is sufficient for non-invasive 
(pTis, i.e. intraepithelial or intramucosal) adenocarcinomas [IV, B]. 
 The presence of invasive carcinoma (pT1) in a polyp requires a thorough 
review with the pathologist and surgeon. High-risk features mandating 
surgical resection with lymphadenectomy include lymphatic or venous 
invasion, grade 3 differentiation, significant (grade >1) and tumour 
budding [IV, B]. 
 Laparoscopic colectomy can be safely carried out for colon cancer when 
technical expertise is available in the absence of contraindications, in view 
of reduced morbidity, improved tolerance and similar oncological 
outcomes [I, C]. 
 Obstructive CRCs can be treated in one- or two-stage procedures, as 






Pathological reporting should be carried out at the time of surgery to precisely 
define nodal spread of disease and extension of the tumour through the bowel 
wall and onto adjacent structures, as well as to assess biopsies when a suspicion 
of liver or peritoneal metastases has been identified by the surgeon. The standard 
assessment should include [47]: 
 morphological description of the specimen; 
 surgical procedure carried out; 
 definition of tumour site and size;  
 presence or absence of macroscopic tumour perforation; 
 histological type and grade; 
 extension of tumour into the bowel wall and adjacent organs (T stage);  
 distance of cancer from resected margins (proximal, distal and radial);  
 presence or absence of tumour deposits;  
 lymphovascular and/or perineural invasion; 
 presence of tumour budding [37]; 
 site and number of removed regional lymph nodes and their possible 
infiltration by cancer cells (N stage);  
 involvement of other organs (e.g. peritoneum) if submitted either removed 
or biopsied (M stage)  
 Mismatch repair (MMR)/microsatellite instability (MSI) status of the 
tumour 
The pathological stage must be reported according to the Union for International 
Cancer Control (UICC) tumour, node, metastasis (TNM) classification, 8th edition 
[48] (see Supplementary Table S1, available at Annals of Oncology online). 
 
Recommendation: 
 A standard surgical/pathological report should include specimen 
description, and surgical procedure, tumour site and size, macroscopic 
tumour perforation, histological type and grade, extension into the bowel 
wall and adjacent organs, distance of cancer from resected margins 




lymphovascular and/or perineural invasion, tumour budding, site and 
number of removed and involved regional lymph nodes, MMR/MSI status 
and involvement of other organs [IV, A]. 
 
RISK ASSESSMENT  
Definitive decisions regarding adjuvant treatment indication can only be made 
after discussing in detail the risk/benefit ratios of available options with the 
patient. To this end, the risk of tumour recurrence must be integrated with 
expected benefits and complications from the given adjuvant treatment (see 
Figure 2). 
 
Assessment of recurrence risk and expected benefits from adjuvant 
therapy  
The assessment of risk of recurrence is important in deciding when to 
recommend systemic adjuvant treatment with the aim of reducing risk of relapse 
and death. The risk of relapse after colon cancer resection is estimated by 
integrating the clinicopathological features of the tumour with the molecular 
marker MMR/MSI status [49].  
TNM staging remains the most relevant histological criteria for risk assessment 
after surgery of colon cancer. Reported 5-year survival rates after surgical 
resection alone are 99% for stage I, 68%–83% for stage II and 45%–65% for 
stage III disease [48]. 
In addition, for intermediate stage II, further parameters need consideration to 
fine-tune the evaluation of risk given the observed variability on prognosis [II] [49]: 
Major prognostic parameters for stage II risk assessment [II] [ 48–50]:   
 Lymph nodes sampling <12;  
 pT4 stage including perforation;  
 




 High grade tumour;  
 Vascular invasion; 
 Lymphatic invasion;  
 Perineural invasion;  
 Tumour presentation with obstruction;  
 High preoperative CEA. 
 
In general, it has been established that adjuvant systemic therapy decreases the 
risk of death by an absolute 3%–5% in high-risk stage II colon cancer with single-
agent 5-fluorouracil (5-FU) and by 10%–15% in stage III disease with 
fluoropyrimidines alone, with a further 4%–5% improvement with oxaliplatin-
containing combinations [I, A].  
MSI/MMR status is the most validated prognostic molecular marker used in 
deciding adjuvant therapy next to clinical prognostic factors.  
Deficient DNA MMR status can be identified by immunohistochemistry detecting 
loss of MMR protein expression (MLH1, MSH2, MSH6 or PMS2), or by 
polymerase chain reaction (PCR) assays of MSI status (microsatellite mutations). 
Determining MSI/MMR status in localised colon cancer patients has two 
objectives: to characterise the prognosis and prediction of adjuvant benefit and 
determine potential genetic predisposition.  
MSI/MMR status determination is important to rule out Lynch syndrome. The 
presence of MSH2 and or MSH6 loss by IHC indicates suspicion of Lynch 
syndrome, while MLH1 and PMS2 loss needs to be investigated further by 
determining BRAF mutation or hypermethylation of the promoter region of 
hMLH1. The identification of either of these alterations suggests with high 
probability the presence of a MLH1 gene somatic acquired alteration rather than 
Lynch syndrome [11]. Besides its implications for Lynch syndrome diagnosis, 
MSI/MMR status defines, in localised colon cancer, a subgroup of patients with a 
better prognosis and less expected benefit from chemotherapy [51-55]. In 
particular, MSI/MMR may be useful to identify a small (10%–15%) subset of stage 




fluoropyrimidines have not been demonstrated and thus adjuvant chemotherapy 
should not be indicated [I, A] [51-55]. 
Nomograms have been developed as tools to standardise decision-making in the 
adjuvant setting; however, their use is not widely implemented [56].  
 
 
Assessment of risk of complications from adjuvant treatment: 
Administration of an adjuvant treatment should only be done by experienced 
sites, with a good knowledge of side-effects and (necessary) dose reduction 
schedules. Despite the proven benefit for patients with stage III and II disease, 
the (relative) counter-indications have to be considered: E.g. Eastern 
Cooperative Oncology Group (ECOG) performance status >2, uncontrolled 
infection, severe liver and renal dysfunction and heart failure [New York Heart 
Association (NYHA) III and IV]. Furthermore, other life-prognosis determining 
comorbidities have to be taken into account.  
Dihydropyrimidine dehydrogenase (DPD) is the main enzyme involved in 
fluoropyrimidine metabolism. Approximately 3%–5% of patients have 
deficiencies of DPD function due to genetic polymorphisms leading to increased 
fluoropyrimidine toxicity, that can be lethal [57]. Based on the recommendation of 
the Pharmacovigilance Risk Assessment Committee (PRAC) of the European 
Medicines Agency (EMA) dated the 13 of March 2020, testing for DPD 
insufficiency should be conducted before initiating fluoropyrimidine based 
chemotherapy [III, A]. There are two main ways to assess DPD functionality: 
through genotyping the DPYD gene or through phenotyping DPD function.  
Genotyping identifies pathologic polymorphisms in the DPYD gene: mainly 
DPYD*2A, c.1679T>G, c.2846A>T or c.1236G>A [56]. In the presence of a 
heterozygous polymorphism, fluoropyrimidine dose should be reduced by 50%, 
while with homozygous polymorphisms, fluoropyrimidines should not be used 
due to the high risk of complications [III, A], according to a Dutch cohort 
observational trial [56]. Phenotyping allows assessment of DPD functionality by 
measuring the dihydrouracil/uracil ratio in blood [58]. For levels >0.16 ng/ml dose 




contraindicated [III, A] [57]. In this situation raltitrexed may be an option for those 
patients with high risk of recurrence [V] [59]. 
Age is another criterion for risk assessment in the adjuvant setting although 
remains controversial. Analyses from a Canadian database (n= 2.801) in Ontario 
indicate that patients in stage III disease between the age of 70–79 years 
received adjuvant treatment in 68% and for patients >80 years in 24% [59]. In this 
retrospective analysis, all age groups benefited about the same level. However, 
the indication for an adjuvant treatment had to be associated with the Charlson 
Comorbidity Index, ensuring that only ‘fit’ elderly patients receive an adjuvant 
treatment. However, all generalisations from clinical randomised trials are difficult 
to do, since patients >75yrs are underrepresented and/or excluded.  
On the other hand, the addition of oxaliplatin to any fluoropyrimidine should be 
used with caution in this population [60, 61]. A pooled analysis from 4 randomised 
trials NSABP-C08, XELOXA, X-ACT and AVANT has shown that in all age 
groups, treatment with oxaliplatin can be considered, if clinically indicated [62]. 
The Hazard Ratio (HR) for overall survival (OS) with oxaliplatin was 0.78 for 
patients of 70yrs or older; however, younger patients experienced a greater 
benefit (HR 0.62) and had a significantly lower rate of toxicity. Similar data were 
demonstrated in the NO16968 trial (XELOX versus bolus 5FU/FA: HR for OS in 
patients 70yrs or older: 0.91 (0.66-1.26) versus 0.80 at younger patients) [61]. A 
similar existing, but reduced benefit also occurred in the analysis of the ACCENT 
database [63].   
 
 
Use of personalised medicine in localised colon cancer/biomarkers for risk  
assessment 
Besides MSI status, other genetic markers, e.g. of RAS and BRAF mutations are 
not recommended for the routine assessment of risk of recurrence in non-
metastatic patients, based on their lack of utility in the adjuvant decision-making 
process [64]. However other biomarkers such as gene signatures, 
Immunoscore™ and postoperative circulating tumour DNA (ctDNA) have 
demonstrated some benefit in determining the risk of recurrence and can be 




adjuvant decision making in difficult cases [65-68].     
Gene signatures have emerged as potential candidates for prognostic 
stratification in locoregional disease. At the time of writing, only Oncotype DX® 
[65] and GeneFx® Colon [66] have been validated in multivariate analysis of 
independent prospective randomised cohorts of stage II colon cancer with 
formalin-fixed paraffin-embedded (FFPE) tumour samples. Although routine 
clinical utility is not warranted due to lack of predictive value for chemotherapy 
benefit and the small prognostic differentiation margins between high, 
intermediate and low scores, their use might be considered in complementing 
clinicopathological information on intermediate-risk stage II scenarios: i.e. to treat 
T3 N0 classified as high risk by the signature, or for avoiding chemotherapy in T4 
N0 classified as low risk by the signature [II, C].  
Immunoscore™ has been recently validated in a large prospective cohort of 
>2500 patients TNM stage I-III [67]. Immunoscore™ was a strong predictor for 
time to recurrence, OS and disease-free survival (DFS) (all P<0.0001), 
independently of patient age, sex, MSI and other existing prognostic factors. 
Immunoscore™ had the highest relative contribution to the risk of all clinical 
parameters, including the UICC TNM classification system [67]. Therefore, 
Immunoscore™ could help refine the prognosis of early colon cancer patients in 
conjunction with the TNM scoring [III, C]. However, its role in predicting 
chemotherapy benefit is uncertain and firm evidence of its prognostic role in a 
stage II-only dataset is currently lacking. 
Finally, ctDNA monitoring, also known as liquid biopsy, is a promising tool under 
investigation to identify patients with high risk of recurrence after primary tumour 
resection. Indeed, ctDNA detection after stage II colon cancer resection has been 
demonstrated to provide direct evidence of residual disease and to identify 
patients at very high risk of recurrence [68]. The results of ongoing trials 
investigating the role of ctDNA as a tool to stratify patient’s risk of relapse and to 
determine allocation to different adjuvant therapeutic strategies must be awaited 
before this is accepted in routine practice. The CIRCULATE-IDEA and de 
Circulatie-Europa collaborations seek to pool the data coming from the main 
national trials exploring ctDNA follow-up in the adjuvant setting. The results of 




making process.  
 
Recommendations: 
 Adjuvant therapy options should be fully discussed with the patient, taking 
into consideration tumour risk of recurrence, expected benefit from 
chemotherapy and risk of complications. 
 The risk of relapse after a colon cancer resection should be assessed by 
integrating the TNM staging, MMR/MSI status and number of lymph nodes 
sampled (+/- 12) [III, A]. 
 Other additional clinicopathological features such as the histological 
subtype and grading, lymphatic or venous or perineural invasion, lymphoid 
inflammatory response, involvement of resection margins and serum CEA 
should be taken into consideration for ‘fine-tuning’ the risk assessment on 
stage II tumours [III, A]. 
 Patient age alone has no predictive value for or against the indication to 
an adjuvant treatment and must be considered in the context of (potential) 
benefit, underlying risk for relapse, life expectancy in relation to (biological) 
age and comorbidities. However, it can be generalised that benefits of 
treatment with both, fluoropyrimidines alone and plus/minus oxaliplatin, 
seem to be more limited, with a higher likelihood for toxicity.  
 MSI/MMR status is the only validated molecular marker used in adjuvant 
decision making and should be determined in stage II CRC. In stage III, 
usage of MMR status is limited to detect and identify Lynch syndrome [IV, 
A]. 
 DPD genotyping or phenotyping is strongly recommended before initiating 
fluoropyrimidine-based adjuvant therapy according to regulatory bodies 
[III, A]. 
 Gene expression signatures are not recommended for routine practice due 
to lack of predictive value for chemotherapy benefit; however, clinicians 
and patients may consider their use to complement clinicopathological 
information in intermediate risk stage II scenarios although their role in 




 Immunoscore™ could be considered to refine the prognosis of early colon 
cancer patients used in conjunction with the TNM scoring and thus adjust 
the chemotherapy decision-making process in stage II and even in low-
risk stage III patients [III, C], although its role in predicting chemotherapy 
benefit is uncertain. 
 
TREATMENT OPTIONS 
Stage III disease  
The current standard of care for adjuvant therapy in stage III colon cancer is a 
combination of fluoropyrimidine and oxaliplatin. The benefit of these 
combinations over fluoropyrimidine monotherapy, the prior standard of care, has 
been demonstrated in three landmark trials: MOSAIC, NSABP C-07 and 
XELOXA. All showed significant improvement in DFS compared with 
fluoropyrimidine as single agent [69-71]. The MOSAIC study used an infusional 
fluoropyrimidine regimen in both arms [leucovorin/5-fluorouracil (LV5FU2) and 
leucovorin/5-fluorouracil/oxaliplatin (FOLFOX)], the NSABP C-07 study used a 
bolus fluoropyrimidine regimen in both arms [Roswell Park and leucovorin/5-
fluorouracil /irinotecan/oxaliplatin (FLOX)], whereas the XELOXA study used a 
bolus fluoropyrimidine regimen (Mayo Clinic or Roswell Park) compared with 
capecitabine plus oxaliplatin (CAPOX). The MOSAIC and NSABP C-07 studies 
included both stage II and stage III colon cancer, while the XELOXA study 
included only stage III colon cancer.  
Although the chemotherapy regimens in the three studies were different, the 
addition of oxaliplatin resulted in a similar reduction in risk of recurrence in all 
three studies (23% in MOSAIC and 20% in NSABP C-07 and XELOXA). With 
longer follow-up, all three trials showed improved OS from the addition of 
oxaliplatin with a risk reduction of death of 16% in MOSAIC, 12% in NSABP C-
07 and 17% in XELOXA [62, 69,72]. However, a significant improvement in OS 
was only shown to be significant for stage III colon cancer.   
FOLFOX and CAPOX remain the current standard of care. As the FLOX regimen 




FLOX is not currently recommended in clinical practice; in addition, irinotecan, 
cetuximab and bevacizumab have not demonstrated clinical activity in the 
localised setting and therefore they should never be used as adjuvant treatment 
in this setting [I, E] [73-77]. 
 
IDEA collaboration, choice of regiment and treatment duration of adjuvant 
treatment  
The major cumulative toxicity from a fluoropyrimidine/oxaliplatin doublet is 
sensory peripheral neuropathy. Worldwide, there have been six studies 
investigating whether 3 months of adjuvant chemotherapy is non-inferior to 6 
months treatment, with the aim of thereby diminishing the incidence of 
neuropathy and healthcare costs. These six trials have been examined 
prospectively by an international collaboration and published as the IDEA study 
[78]. In this pooled analysis, 12,834 patients with stage III colon cancer were 
randomised to receive either 3 months or 6 months of a 
fluoropyrimidine/oxaliplatin doublet (either FOLFOX or CAPOX); the choice of 
regimen was mainly the clinician’s choice and not randomised. The 3-year DFS 
rates was similar (overall: 74.6% and 75.5% for 3 months and 6 months, 
respectively) but the pre-defined non-inferiority margin, accepting a 12% 
decrease as upper limit of inferiority to be ruled out, was not confirmed in the 
overall study population (HR, 1.07; 95% confidence interval [CI], 1.00 to 1.15).  
However, sensory peripheral neuropathy grade 2 or worse was significantly 
reduced from 34% with 6 months of treatment to 11% with 3 months of treatment. 
In the IDEA study, the treatment duration depends on the choice of regimen. For 
patients receiving CAPOX, 3 months treatment was non-inferior with 3-year DFS 
of 75.9% and 74.8% for 3 and 6 months respectively whereas for FOLFOX, 3 
months treatment was inferior with 3-year DFS of 73.6% and 76.0% for 3 and 6 
months respectively. Therefore, non- inferiority of the shorter regimen was seen 
for CAPOX (HR, 0.95; 95% CI, 0.85 to 1.06) but not for FOLFOX (HR, 1.16; 95% 
CI, 1.06 to 1.26).  
Thus, both CAPOX for 3 months and FOLFOX for 6 months can be 




A]. It is important to mention that CAPOX and FOLFOX assignment in the IDEA 
trials was not randomised, precluding any formal comparison between the two 
regimens. 
CAPOX mitigates the need for central venous access and decreased 
neurotoxicity rates if 3 months is adequate but is associated with more diarrhoea 
and hand-foot syndrome than FOLFOX; thus, it may be relatively contraindicated 
if a patient has an ileostomy and in cases of renal insufficiency. FOLFOX has 
higher reported neutropenia rates. Immediate oxaliplatin cessation following 
occurrence of grade >1 neuropathy is recommended in all cases (whatever the 
regimen and treatment duration) to avoid long-lasting symptomatic neurotoxicity 
that will impair the patient’s quality of life.  
 
Definition of risk groups in stage III 
The IDEA study also conducted an exploratory analysis based on risk subgroups. 
In the lower-risk subgroup (defined as patients with T1, T2 or T3 with N1 disease), 
3 months of adjuvant therapy appeared to be sufficient, when CAPOX was 
chosen [II, B]. In the higher-risk group (patients with T4 or N2 or both), 6 months 
of treatment may be necessary, especially when FOLFOX is the chosen regimen, 
but also with CAPOX, which missed the non-inferiority margin on this subgroup 
[II, B].  
However, the panel believes that the establishment of stage III risk subgroups 
should be used with caution, since this was a post hoc analysis on the IDEA 
collaboration: T4 versus T1–3 and N2 versus N1 subgroups analyses were pre-
specified in the protocol but their combination in high versus low-risk subgroups 
was not, and moreover, its interaction test was not significant (P=0.11). Thus, the 
panel agrees that the established high- versus low-risk subgroups in stage III 
based on IDEA should have level of evidence [V] (see Figure 3 for adjuvant 
treatment recommendations in stage III). 
 
Recommendations: 




oxaliplatin constitute the bases for stage III colon cancer adjuvant 
treatment [I, A; European Society for Medical Oncology-Magnitude of 
Clinical Benefit Scale (ESMO-MCBS) v1.1 score: B]. 
 The length of oxaliplatin-based adjuvant treatment for stage III colon 
cancer based on the IDEA data may be tailored to 3 or 6 months for 
CAPOX [I, A] or 6 months for FOLFOX [I, A] also taking into consideration 
pathological risk characteristics, patient comorbidity and risk assessment. 
 Further adaptation of the treatment according to risk subgroups: 3 months 
for CAPOX (T1–3 N1 disease), 6 months for CAPOX (T4 or N2 disease) 
or 6 months for FOLFOX (T1–3 N1 or T4 or N2 disease) based on IDEA 
collaboration should be made with caution, since this was based on a post 
hoc analysis, non-significant for interaction [V].  
 For patients not fit for or not tolerating oxaliplatin, either capecitabine or 
LV5FU2 (de Gramont) infusion are acceptable adjuvant regimens for a 6-
month duration [I, A]. 
 
Stage II disease 
 
As already discussed, there are major and minor clinicopathological factors that 
impact on the risk of relapse on stage II colon cancer. The presence of major 
factors including pT4 stage or <12 lymph nodes assessed confers increased risk 
of recurrence, while the presence of other additional risk factors is less 
significantly associated with risk of relapse [48-50]. While follow-up is an option 
for low-risk stage II patients, chemotherapy is recommended for intermediate and 
high-risk patients [I, B]. 
Although the de Gramont is the only regimen that has demonstrated efficacy in 
the setting [I, B], capecitabine is an option especially with contraindications for 
insertion of a central line [V]. It is also felt by the panel members that patients 
with high risk, patients with pT4 and/or less <12 lymph nodes or accumulation of 
several intermediate risk factors, might be considered for the addition of 
oxaliplatin therapy based on a trend to an increased benefit, although this did not 
achieve statistical significance in the stage II high-risk subgroup analysis of 
MOSAIC trial [I, B] [69]. For this high-risk population, the IDEA trial explored the 




results to those reported for stage III patients, a non-proven non-inferiority for 3 
months of treatment and, there was a proven non-inferiority of CAPOX and 
inferiority of FOLFOX 3 months when compared with 6 months of FOLFOX [79] 
with all the limitations of these post-hoc analyses as stated before. The presence 
of MSI/MMR in localised disease confers better prognosis and less benefit to 
adjuvant therapy so chemotherapy should be indicated with caution and always 
in combination with oxaliplatin [51–55] (see Figure 4 for integration of 
clinicopathological and molecular factors with therapeutic recommendations).  
Lifestyle factors are likely to have an important impact on survival following 
adjuvant chemotherapy in either stages II or III patients, as reported for physical 
activity and nut consumption [80, 81]. In addition, aspirin reduces the risk of polyp 
formation and may also improve survival after adjuvant chemotherapy in PI3K-
mutant colon cancer patients (approximately 20% of all patients) [82]. The ADD-




 For patients with low-risk stage II colon cancer, follow-up is recommended 
[I, A].  
 For patients with intermediate risk (non-MMR/MSI + any risk factor except 
pT4 or <12 lymph assessed) 6 months fluoropyrimidines should be 
recommended [I, B]. 
 Patients with high-risk stage II (pT4 or <12 lymph nodes or multiple 
intermediate risk factors, regardless of MSI) may be considered for the 
addition of oxaliplatin [I, C]. 
 Patients with high-risk stage II colon cancer may be considered for 3 
months of CAPOX, as the IDEA-pooled analysis showed non-inferiority of 
3 months of CAPOX and inferiority of 3 months of FOLFOX when 
compared with 6 months of FOLFOX, with all the limitations of post-hoc 





Timing of adjuvant chemotherapy 
Delay between surgery and the beginning of adjuvant chemotherapy is a matter 
of debate. In view of the evidence, it is important to commence adjuvant 
chemotherapy as soon as possible after surgery and ideally not later than 8 
weeks [II, B]. A meta-analysis of 14 studies showed that a delay of >8 weeks in 
starting adjuvant chemotherapy is associated with a higher relative risk of death 
(HR 1.20; 95% CI 1.15–1.26, P=0.001) [83]. This observation has been confirmed 
by other groups [84, 85]. However, population-based studies have shown that 
adjuvant chemotherapy might still provide some benefit, even with delays up to 
5–6 months [86, 87], but it seems that the benefit of adjuvant chemotherapy is 
minimal or completely lost if treatment is started >6 months after surgery.  
 
Recommendations:  
 It is important to start adjuvant chemotherapy as soon as possible after 
surgery and ideally not later than 8 weeks [I, A]. 
 
FOLLOW-UP AND LONG-TERM IMPLICATIONS 
Follow-up 
Overall, between 30% and 50% of all patients treated for localised colon cancer 
will eventually relapse and die from the disease [88, 89]. The main goal of follow-
up protocols is detecting relapse on an early basis, thereby maximising patient 
survival on the metastatic setting. Systematic reviews have shown disparate 
results regarding the use of intensive follow-up as a tool to increase OS [90, 91]. 
However, it has been shown that there is an advance in the detection of 
recurrences [II, B] with intensive follow-up [91]. Detection of isolated local 
recurrences was increased in the intensive group (15% compared with 9%, with 
risk ratio 1.61 and P=0.011), along with a small, non-significant increase in the 
detection of hepatic metastases [91]. However, heterogeneity of the studies 
included in these meta-analyses does not allow precise assessment of algorithms 




assessment, CEA testing and/or liver imaging achieve significant improvements 
in survival, though all studies considering liver imaging also included blood CEA 
monitoring [92].  
CT scan including optimal liver assessment has been shown to be more sensitive 
than ultrasonography (0.67 compared with 0.43) for liver relapse follow-up and, 
in addition, can detect chest recurrences. On the other hand, liver MRI may be 
an alternative when a CT scan has shown confusing liver lesions [93]. 
Regarding the timing and duration of follow-up, protocols need to be sensitive to 
the patterns of relapse of colon cancer. Among recurring patients, 80% of 
relapses occur during the first 3 years and an additional 15% between the 3rd 
and 5th year, which supports a more intensive follow-up during the first 3 years 
and a stop after 5 years [88, 93]. 
In addition to CEA and CT scans, colonoscopies should also be included on the 
follow-up since metachronous primary cancer can be detected with an incidence 
of 0.7% within the first 2 years after curative surgery [94]. However, there is no 
indication for intensive endoscopic follow-up. If a colon without tumour or 
adenoma is observed 1 year after resection, colonoscopy should be carried out 




 Intensive follow-up allows earlier detection of relapses in patients at risk 
[II, B].  
 History and physical examination and CEA determination are advised 
every 3–6 months for 3 years and every 6–12 months at years 4 and 5 
after surgery [II, B].  
 Colonoscopy must be carried out at year 1 and every 3–5 years thereafter, 
looking for metachronous adenomas and cancers [III, B].  
 CT scan of chest and abdomen every 6-12 months for the first 3 years can 
be considered in patients who are at higher risk of recurrence according 




 Other laboratory and radiological examinations are of unproven benefit 
and must be restricted to patients with suspicious symptoms [V, C].  
Long-term implications/survivorship care plans 
CRC survivors represent the third largest group of long-term cancer survivors in 
Western countries, ∼11% of this population. For this group, additional post-
therapeutic follow-up interventions have demonstrated to improve patient 
outcomes [95]. In this setting, the primary practitioner should have a significant 
role in collaborating with the oncological teams [96,97].  
Major elements in survivorship care are as follows:  
1. Prevention of recurrent and new cancer (classic end point of follow-up). 
2. Intervention for cancer sequelae and their treatment (rehabilitation).  
3. Assessment of medical and psychological late effects (modern end point 
of follow-up).  
4. Health promotion (lifestyle promotion, comorbidity prevention, etc.). 
Most long-term survivors of CRC report good quality of life following treatment, 
but several problems are still observed [98]. A significant proportion of patients 
have persistent bowel dysfunction. It is important to refer for dietary counselling 
and suggest use of over-the-counter medications (e.g. fibre laxatives, stool 
softeners, antidiarrheals). Colostomies and ileostomies represent also a source 
of physiologic distress and disturbances at the level of social functioning. Patients 
should be encouraged to take part in ostomy management programmes and 
psychological distress management programmes must be recommended in case 
of discomfort with their body changes.   
Colon cancer survivors experience higher rates of sexual distress and 
psychological depression [98]. Assessment of distress should be considered, but 
evidence on the effectiveness of psychosocial interventions among survivors of 
CRC is limited. Patients should be encouraged to maintain a healthy lifestyle 
including exercise, quitting smoking, avoidance of excessive alcohol intake and 
adoption of a healthy diet rich in vegetables, fruit and berries adapted to the 






 Long-term follow-up, rehabilitation and survivorship care programs should 
be implemented, aiming at detection of recurrent or new cancers, 
assessment and management of late and psychosocial effects and 
implementation of health promotion measures [III, A]. 
 
METHODOLOGY 
These Clinical Practice Guidelines were developed in accordance with the ESMO 
standard operating procedures for Clinical Practice Guidelines development 
(http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology). The relevant 
literature has been selected by the expert authors. An ESMO-MCBS table with 
ESMO-MCBS scores is included in supplementary Table S2, available at 
Annals of Oncology online [100]. ESMO-MCBS v1.1 was used to calculate scores 
for new therapies/indications approved by the EMA since 1 January 2016 
(https://www.esmo.org/Guidelines/ESMO-MCBS). The scores have been 
calculated by the ESMO-MCBS Working Group and validated by the ESMO 
Guidelines Committee. Levels of evidence and grades of recommendation have 
been applied using the system shown in supplementary Table S3, available at 
Annals of Oncology online) [101]. Statements without grading were considered 
justified standard clinical practice by the experts and the ESMO Faculty. This 
manuscript has been subjected to an anonymous peer review process. 
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Table 1. Diagnostic work-up for localised CRC 
 
Local assessment LoE, GoR 










CT colonography (when complete colonoscopy is not feasible) I, A 
MRI abdominal (to clarify ambiguous lesions or define pT4b) II, A 
Laboratory work-up 
Complete blood count II, A 
Coagulation II, A 
Liver function panel II, A 
Kidney function panel II, A 
Albumin III, A 
CEA III, A 
 
CEA, carcinoembryonic antigen; CRC, colorectal cancer; CT, computed 
tomography; GoR, grade of recommendation; LoE, level of evidence; MRI, 























Figure 3. Recommendations for adjuvant treatment of stage III colon 
cancer  
 
CAPOX, capecitabine plus oxaliplatin; FOLFOX, 
leucovorin/fluorouracil/oxaliplatin; MCBS, magnitude of clinical benefit scale; 





Figure 4. Recommendations for adjuvant treatment of stage II colon 
cancer  
 
CAPOX, capecitabine plus oxaliplatin; CEA, carcinoembryonic antigen; 
FOLFOX, leucovorin/fluorouracil/oxaliplatin; MSI, microsatellite instability; MSS, 
microsatellite stability. 
a For pT4 MSI: pT4  is a major risk factor but adjuvant chemotherapy benefit in 









Figure 5. Recommendations for follow up after curative resection 
 
CEA, carcinoembryonic antigen; CT, computed tomography; mCRC, metastatic 
colorectal cancer. 
 
